LONDON, United Kingdom, June 18, 2026
GSK plc and Spero Therapeutics have achieved a major milestone in the fight against complicated urinary tract infections (cUTIs) following the U.S. Food and Drug Administration (FDA) approval of Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic approved in the United States. The approval marks a significant advancement in anti-infective medicine and addresses a growing need for effective treatment options against multidrug-resistant bacterial infections. Designed for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options, Utebzi offers a convenient outpatient alternative to intravenous carbapenem therapy. The regulatory decision is supported by positive Phase III clinical data demonstrating non-inferiority to standard intravenous treatment, potentially transforming how serious urinary tract infections are managed while reducing dependence on hospital-based care. The approval also strengthens GSK’s expanding anti-infectives portfolio and highlights continued innovation in combating the global challenge of antimicrobial resistance.
FDA Approval Introduces a New Era in cUTI Treatment
Complicated urinary tract infections affect more than three million patients annually in the United States, with treatment failure impacting a substantial proportion of individuals, particularly those infected with multidrug-resistant pathogens. These infections contribute significantly to healthcare utilization and costs while creating treatment challenges for clinicians. Until now, carbapenem antibiotics, widely regarded as the standard of care for severe and resistant bacterial infections, have only been available through intravenous administration. This limitation often requires hospitalization or specialized infusion services, creating burdens for patients and healthcare systems alike.
The approval of Utebzi (tebipenem pivoxil) introduces the first oral carbapenem option, allowing eligible patients to receive advanced antibiotic therapy outside the hospital setting. Experts believe this innovation could improve patient convenience, reduce hospital resource utilization, and expand access to effective treatment for resistant infections while supporting antimicrobial stewardship efforts.
Phase III Trial Demonstrates Strong Clinical Performance
Advertisement
The FDA approval was supported by findings from the pivotal Phase III PIVOT-PO trial, a global randomized study comparing oral tebipenem pivoxil with intravenous imipenem-cilastatin in hospitalized adults with complicated urinary tract infections. Results demonstrated that tebipenem pivoxil achieved non-inferiority to the intravenous comparator, with an overall clinical and microbiological success rate of 58.5%, compared with 60.2% for imipenem-cilastatin. The study confirmed that an oral treatment could deliver outcomes comparable to an established hospital-based intravenous therapy.
Importantly, the safety profile of tebipenem pivoxil was generally consistent with other carbapenem antibiotics, with the most commonly reported adverse events including mild to moderate diarrhea and headache. These findings underscore the therapy’s potential to provide effective treatment while offering the convenience and flexibility associated with oral administration. The approval represents a landmark achievement in antibiotic development, particularly as resistance continues to threaten the effectiveness of existing antimicrobial therapies worldwide.
Expanding Access and Addressing Antimicrobial Resistance
The approval of Utebzi is expected to have significant implications for both patients and healthcare providers. By offering an effective oral alternative to intravenous carbapenems, the therapy has the potential to reduce hospital admissions, shorten treatment-related healthcare burdens, and improve quality of life for patients managing complicated infections. The drug also supports broader public health efforts aimed at addressing the escalating threat of antimicrobial resistance, which remains one of the most pressing challenges in modern medicine.
Through their longstanding collaboration, GSK and Spero Therapeutics have successfully advanced a therapy that combines clinical effectiveness with practical treatment accessibility. The achievement also reflects years of research, development, and regulatory collaboration, culminating in a product that may redefine treatment approaches for resistant bacterial infections. With commercial availability expected by the end of 2026, Utebzi represents an important advancement in infectious disease management and reinforces the critical role of innovative antibiotics in safeguarding global health.
Source: GSK, Spero Therapeutics press release
